Myeloma Paper of the Day, December 2nd, suggested by Robert Orlowski
Robert Orlowski shared a post on X:
“Myeloma Paper of the Day: Phase 2 of bendamustine, rituximab and bortezomib in relapsed/refractory Waldenstrom macroglobulinaemia shows ORR 84.6% (11% CR), PFS @ 18, 24 and 30 mos of 84.2%, 81.5%, 78.8%, OS @ 18 mos 92.1%, and 50% grade 3-4 heme toxicity.”
Authors: Giulia Benevolo, Daniela Drandi, Nicoletta Villivà, Anna Castiglione, Federico Monaco, Carola Boccomini, Daniela Dessi, Catello Califano, Luigi Curreli, Federica Cavallo, Annarita Conconi, Gianluca Gaidano, Francesca Gaia Rossi, Tommaso Caravita di Toritto, Martina Ferrante, Donato Mannina, Patrizia Tosi, Giuseppe Pietrantuono, Gerardo Musuraca, Michele Merli, Roberto Sartori, Monica Tani, Roberto Freilone, Marzia Varettoni, Simone Ferrero.
More posts featuring Robert Orlowski.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023